Stryker Q1 Sales Rise 2.6% Miss Estimates

Stryker Q1 2026 net sales rose 2.6% YoY but fell short of analyst forecasts amid a cyber incident.
Adjusted EPS dropped 8.5% to $2.60, missing expectations, while organic sales grew 2.4% driven by 2.1% volume increase.
MedSurg and Neurotechnology segment sales rose 5.0%; Orthopaedics flat overall but showed 4.1% organic growth from volume.
Company kept FY2026 guidance of 8.0‑9.5% organic sales growth and $14.90‑$15.10 EPS, expecting modest pricing and favorable FX.